Andrew Baker Campbell

Andrew Baker-Campbell Andrew Baker-Campbell is a seasoned leader in medical technology innovation and a board member at pioneering technology development organisation TTP. He is Co-Founder and Chairperson of LEX Diagnostics, a point-of-care diagnostics company working towards regulatory approval following a successful 4,000-patient clinical trial. Andrew has led the company through key milestones - from first IP filings, to raising over $40M in strategic investment. LEX plans to launch their revolutionary 5-minute PCR test for Flu A, Flu B, and COVID-19 in winter 25/26. Andrew also leads the HealthTech division at TTP, helping some of the world’s most ambitious MedTech and Pharma companies bring game-changing products to market. His teams of engineers, scientists and designers operate at the forefront of complex, multidisciplinary innovation - spanning biosensors, surgical robotics, neuromodulation, drug delivery, ophthalmic innovation and beyond. Andrew has led teams that have delivered breakthrough technologies for global leaders including Philips, Bayer and Becton Dickinson, as well as supported high-growth start-ups bringing first-of-a-kind products to market. He is the author of several patents in sensing and microdevice technologies and brings deep expertise in technology innovation, IP generation and licensing, and business development. Andrew earned his PhD in Optoelectronics from the University of Cambridge.